MA49896A - Nouveaux analogues d'insuline acylés et leurs utilisations - Google Patents

Nouveaux analogues d'insuline acylés et leurs utilisations

Info

Publication number
MA49896A
MA49896A MA049896A MA49896A MA49896A MA 49896 A MA49896 A MA 49896A MA 049896 A MA049896 A MA 049896A MA 49896 A MA49896 A MA 49896A MA 49896 A MA49896 A MA 49896A
Authority
MA
Morocco
Prior art keywords
insulin analogues
acylated insulin
new acylated
new
analogues
Prior art date
Application number
MA049896A
Other languages
English (en)
Inventor
Jakob Brandt
Bo Falck Hansen
Grith Skytte Olsen
Ingrid Pettersson
Lauge Schäffer
Rita Slaaby
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49896A publication Critical patent/MA49896A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
MA049896A 2017-08-17 2018-08-16 Nouveaux analogues d'insuline acylés et leurs utilisations MA49896A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17186612 2017-08-17
EP17204872 2017-12-01

Publications (1)

Publication Number Publication Date
MA49896A true MA49896A (fr) 2020-06-24

Family

ID=63165388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049896A MA49896A (fr) 2017-08-17 2018-08-16 Nouveaux analogues d'insuline acylés et leurs utilisations

Country Status (19)

Country Link
US (2) US10919949B2 (fr)
EP (1) EP3668892A1 (fr)
JP (2) JP2020531451A (fr)
KR (1) KR20200038502A (fr)
CN (1) CN111032685A (fr)
AU (1) AU2018317810A1 (fr)
BR (1) BR112020002364A2 (fr)
CA (1) CA3071686A1 (fr)
CL (1) CL2020000310A1 (fr)
CO (1) CO2020002500A2 (fr)
IL (1) IL272394A (fr)
MA (1) MA49896A (fr)
MX (1) MX2020001434A (fr)
PE (1) PE20211264A1 (fr)
PH (1) PH12020550050A1 (fr)
RU (1) RU2020108281A (fr)
SG (1) SG11202001077UA (fr)
TW (1) TW201917134A (fr)
WO (1) WO2019034726A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
CA3204051A1 (fr) 2021-01-20 2022-07-28 Brian Lian Compositions et procedes pour le traitement de troubles metaboliques et hepatiques

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5616729A (en) 1986-07-17 1997-04-01 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK33591D0 (fr) 1991-02-27 1991-02-27 Novo Nordisk As
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
JP4187796B2 (ja) 1996-12-20 2008-11-26 ノボ ノルディスク アクティーゼルスカブ 酵母で発現されたｎ末端伸長タンパク質
DK1146896T3 (da) 1999-01-26 2002-09-02 Lilly Co Eli Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
AU5144400A (en) * 1999-05-19 2000-12-05 Xencor, Inc. Novel proteins with insulin-like activity useful in the treatment of diabetes
WO2001049742A1 (fr) 1999-12-29 2001-07-12 Novo Nordisk A/S Procede de production de precurseurs d'insuline et d'analogues de precurseurs d'insuline
WO2005054291A1 (fr) 2003-12-03 2005-06-16 Novo Nordisk A/S Insuline monocatenaire
WO2006008238A1 (fr) * 2004-07-16 2006-01-26 Novo Nordisk A/S Procede d'acylation selective
ES2428510T3 (es) 2005-02-02 2013-11-08 Novo Nordisk A/S Derivados de insulina
ATE482977T1 (de) * 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2009022013A1 (fr) 2007-08-15 2009-02-19 Novo Nordisk A/S Analogues de l'insuline comprenant un fragment acyle et alkylène glycol
WO2009112583A2 (fr) 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
EP2910571B1 (fr) 2008-03-18 2016-10-05 Novo Nordisk A/S Analogues de l'insuline acylés, stabilisés à la protéase
JP2012512900A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション インスリン受容体に対して高い活性を示すｙｌ系インスリン様増殖因子
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010080606A1 (fr) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Analogues d'insuline
TW201105346A (en) 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
CA2802485C (fr) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Agonistes de l'insuline a une seule chaine tres actifs au niveau du recepteur a l'insuline
WO2011159882A2 (fr) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Nouveaux agonistes stabilisés de l'insuline
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011163460A1 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Facteurs de croissance insulinomimétiques à base d'yl à activité élevée sur le récepteur de l'insuline
CN103119057B (zh) 2010-06-24 2016-06-15 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
EP2598527A4 (fr) 2010-07-28 2014-01-08 Smartcells Inc Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
JP6392123B2 (ja) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 糖尿病治療のためのｃｔｐ系インスリンアナローグ
CN104364262A (zh) 2011-12-21 2015-02-18 诺沃—诺迪斯克有限公司 N末端修饰的胰岛素衍生物
EP3395358B1 (fr) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Dimères d'un analogue d'insuline
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
EP2931301B2 (fr) 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Procédé pour purifier l'insuline et ses analogues
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US20160193154A1 (en) 2013-07-24 2016-07-07 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
WO2016049190A1 (fr) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Conjugués d'insuline-incrétines
JP6484337B2 (ja) 2014-11-21 2019-03-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． インスリン受容体部分アゴニスト
EP3250225A1 (fr) 2015-01-29 2017-12-06 Novo Nordisk A/S Composition pharmaceutique pour l'administration d'insuline par voie orale comprenant un noyau de comprimé et un enrobage d'alcool polyvinylique
EP3268384B1 (fr) 2015-03-10 2021-11-03 Merck Sharp & Dohme Corp. Procédé de préparation d'insuline recombinante par microfiltration
EP3280450A4 (fr) 2015-04-08 2018-12-12 Merck Sharp & Dohme Corp. Conjugués d'insuline sensibles au glucose
WO2016172269A2 (fr) 2015-04-20 2016-10-27 University Of Utah Research Foundation Analogues d'insuline ayant des peptides à chaîne b raccourcie et procédés associés
US20180244743A1 (en) * 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
TW201717998A (zh) 2015-08-25 2017-06-01 諾佛 儂迪克股份有限公司 新穎胰島素衍生物及其醫學用途
US10745457B2 (en) 2015-09-02 2020-08-18 Merck Sharp & Dohme Corp. Process for obtaining insulin with correctly formed disulfide bonds

Also Published As

Publication number Publication date
CA3071686A1 (fr) 2019-02-21
BR112020002364A2 (pt) 2020-09-01
TW201917134A (zh) 2019-05-01
US20190194285A1 (en) 2019-06-27
JP2020531451A (ja) 2020-11-05
PH12020550050A1 (en) 2020-10-19
PE20211264A1 (es) 2021-07-15
CO2020002500A2 (es) 2020-06-09
CL2020000310A1 (es) 2020-07-10
WO2019034726A1 (fr) 2019-02-21
RU2020108281A (ru) 2021-08-26
RU2020108281A3 (fr) 2022-03-09
CN111032685A (zh) 2020-04-17
US10919949B2 (en) 2021-02-16
SG11202001077UA (en) 2020-03-30
EP3668892A1 (fr) 2020-06-24
US20210094999A1 (en) 2021-04-01
AU2018317810A1 (en) 2020-03-19
IL272394A (en) 2020-03-31
JP2022105082A (ja) 2022-07-12
MX2020001434A (es) 2020-03-20
KR20200038502A (ko) 2020-04-13

Similar Documents

Publication Publication Date Title
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA53652A (fr) Lipides peg de haute pureté et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA53650A (fr) Lipides peg et leurs utilisations
DK3506909T3 (da) 4'-phosphatanaloger og oligonukleotider omfattende samme
MA50618A (fr) Polyrhérapies et leurs utilisations
MA43551A (fr) Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
MA50265A (fr) Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA42036A (fr) Analogues nucléosidiques 5'-substitués
MA42701A (fr) Compositions d'insuline à action rapide
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
DK3263565T3 (da) Cyklisk aminderivat og farmaceutisk anvendelse deraf
MA55083A (fr) Polyribonucléotides et leurs utilisations cosmétiques
BR112018005755A2 (pt) benzamidas substituídas com isoxazolina e análogos como inseticidas.
DK3535397T3 (da) Alfa-v-beta-6-integrin-ligander og anvendelser deraf
DK3548135T3 (da) Kerne-skal-mikronålsindretninger og anvendelser deraf
MA46945A (fr) Exopolysaccharides et leurs utilisations
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
MA44968A (fr) Esters d'oxaborole et leurs utilisations
MA43141A (fr) Nouveaux composés et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
MA52337A (fr) Nouveaux analogues d'oxaborole et utilisations de ces derniers
MA49684A (fr) Arnm modifié codant une glucose-6-phosphatase et utilisations associées
MA49896A (fr) Nouveaux analogues d'insuline acylés et leurs utilisations